Ocugen (OCGN) Stock Price, News & Analysis

Company Overview

Ocugen, Inc. (NASDAQ: OCGN) is a biotechnology company focused on developing gene and cell therapies for blindness diseases and other serious medical conditions. The company’s ophthalmology pipeline includes modifier gene therapies designed to address inherited retinal diseases, including retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration.

Ocugen’s leading candidates include OCU400, an investigational gene therapy for certain inherited retinal diseases, and OCU410 and OCU410ST, investigational therapies being developed for geographic atrophy and Stargardt disease, respectively. The company has also pursued regenerative medicine programs, including cell-based therapies intended to treat retinal disorders.

Founded in 2013 and headquartered in Malvern, Pennsylvania, Ocugen primarily conducts its research and clinical development activities in the United States. The company previously collaborated with Bharat Biotech on the development and commercialization of Covaxin, a COVID-19 vaccine candidate for the U.S. market, but its current strategic focus is on ophthalmic gene and cell therapies. Shankar Musunuri serves as Ocugen’s chairman, chief executive officer and co-founder.

Key Stats

• Today's Range: $0.98 to $1.06
• 50-Day Range: $0.99 to $1.48
• 52-Week Range: $0.97 to $2.73
• Volume: 12.16 million shs
• Average Volume: 7.25 million shs
• Market Capitalization: $339.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.50
• Consensus Rating: Moderate Buy

Ocugen Stock Analysis - MarketRank™

Ocugen scored higher than 30% of companies evaluated by MarketBeat, and ranked 672nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ocugen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Ocugen has a consensus price target of $9.50, representing about 850.0% upside from its current price of $1.00.

Amount of Analyst Coverage

Ocugen has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ocugen are expected to decrease in the coming year, from ($0.25) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ocugen is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ocugen is -3.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

30.18% of the float of Ocugen has been sold short.

Short Interest Ratio / Days to Cover

Ocugen has a short interest ratio ("days to cover") of 28.24, which indicates bearish sentiment.

Change versus previous month

Short interest in Ocugen has recently decreased by 3.40%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ocugen does not currently pay a dividend.

Dividend Growth

Ocugen does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Ocugen this week, compared to 5 articles on an average week.

Search Interest

13 people have searched for OCGN on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days.

MarketBeat Follows

10 people have added Ocugen to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ocugen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $589,110.00 in company stock.

Percentage Held by Insiders

3.95% of the stock of Ocugen is held by insiders.

Percentage Held by Institutions

10.27% of the stock of Ocugen is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/23/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OCGN
• CIK: 1372299
• Web: ocugen.com
• Phone: (484) 328-4701
• Fax: 781-547-4452
• Employees: 116
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Ocugen: $9.50
• High Price Target: $11.00
• Low Price Target: $7.00
• Potential Upside/Downside: +850.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$67.85 million
• Net Margins: N/A
• Pretax Margin: -1,786.27%
• Return on Equity: -127,987.80%
• Return on Assets: -115.95%

Debt

• Debt-to-Equity Ratio: 4.17
• Current Ratio: 0.80
• Quick Ratio: 0.80

Sales & Book Value

• Annual Sales: $4.41 million
• Price / Sales: 76.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.04) per share
• Price / Book: -25.00

Miscellaneous

• Outstanding Shares: 339,110,000
• Free Float: 325,715,000
• Market Cap: $339.11 million
• Optionable: Optionable
• Beta: 2.20